Literature DB >> 10408376

Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies.

J Prechl1, A Tchorbanov, A Horváth, D C Baiu, W Hazenbos, E Rajnavölgyi, I Kurucz, P J Capel, A Erdei.   

Abstract

Single-chain variable fragment (scFv) antibodies are genetically engineered molecules comprising the variable regions responsible for specific binding. scFv that recognize certain surface molecules on professional antigen presenting cells could therefore be suitable for targeting Ag to these cells. We have produced an scFv that recognizes murine complement receptors 1 and 2 (CR1/CR2) and genetically fused it with different numbers of influenza hemagglutinin peptides which contain both B and T cell epitopes. The CR1/CR2 specific hybridoma 7G6 was used for RT-PCR to obtain the variable regions, which were then combined to create an scFv fragment. The influenza hemagglutinin intersubunit peptide HA317-41 (IP) was engineered to the N terminus of the scFv in one, two or three copies. The so obtained IP(1-3)7G6scFv still bound the complement receptors; the peptides in the construct were recognized by the peptide specific monoclonal IP2-11-1 on Western blots and ELISAs. The CR1/CR2 positive B lymphomas A20 and 2PK3 presented the peptide to an I-Ed restricted IP specific T cell hybridoma more efficiently when incubated with the IP(1)7G6 constructs as compared to the free peptide. The results suggest that scFv could work as targeting devices in subunit vaccines.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408376     DOI: 10.1016/s0162-3109(99)00025-9

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  5 in total

Review 1.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

2.  A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.

Authors:  Liudmila Kulik; Finnegan B Hewitt; Van C Willis; Rosa Rodriguez; Stephen Tomlinson; V Michael Holers
Journal:  Mol Immunol       Date:  2015-02       Impact factor: 4.407

3.  Expression of a functional single-chain variable-fragment antibody against complement receptor 1 in Streptococcus gordonii.

Authors:  Jennifer B Knight; Scott A Halperin; Kenneth A West; Song F Lee
Journal:  Clin Vaccine Immunol       Date:  2008-04-02

4.  Generation of gene-engineered chimeric DNA molecules for specific therapy of autoimmune diseases.

Authors:  Vera Gesheva; Zsuzsanna Szekeres; Nikolina Mihaylova; Iliyana Dimitrova; Maria Nikolova; Anna Erdei; Jozsef Prechl; Andrey Tchorbanov
Journal:  Hum Gene Ther Methods       Date:  2012-11-23       Impact factor: 2.396

5.  Built-in adjuvanticity of genetically and protein-engineered chimeric molecules for targeting of influenza A peptide epitopes.

Authors:  Nikola S Kerekov; Iva I Ivanova; Nikolina M Mihaylova; Maria Nikolova; Jozsef Prechl; Andrey I Tchorbanov
Journal:  Immunol Res       Date:  2014-10       Impact factor: 2.829

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.